Nanabiotix, a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, has received the French 2019 Prix Galien Award for Most Innovative MedTech. The Company’s lead product, HENSIFY (NBTXR3) brand name for the treatment of locally advanced Soft Tissue Sarcoma (STS), was recognized after receiving European market approval (CE marking, DM class III, on April 2, 2019) earlier this year. The Prix Galien Award recognizes outstanding biomedical and medical technology product achievements that improve the human condition.
“We are thrilled to receive the 2019 Prix Galien for HENSIFY. It is both humbling and rewarding to know that the efforts of our team and our partners, over more than 15 years, have been recognized in this way, says Laurent Levy (pictured above), CEO of Naobiotix. "At Nanobiotix, we remain committed to changing the face of cancer therapy through disruptive innovation, all with the goal of significantly improving outcomes for patients around the world.”
HENSIFY is a first-in-class “radioenhancer” consisting of an aqueous suspension of crystalline hafnium oxide nanoparticles. The product is administered only once, directly into the tumor, before a patient’s first radiotherapy session. After intratumoral injection, the nanoparticles penetrate the tumor cells and, when activated by ionizing radiation, deliver a larger energy deposit within the tumor where the nanoparticles are present, thereby increasing the tumor-killing effect of treatment without increasing damage to surrounding healthy tissues. HENSIFY has a universal, physical mode of action and is inert within the human body outside of the presence of ionizing radiation.
Moving forward, the company is engaged in global clinical development of the product across fifteen (15) clinical trials in STS and other indications with a primary focus on global registration for the treatment of Head and Neck cancers. These trials include the expansion phase of a European phase I evaluating the safety and feasibility of NBTXR3 activated by radiation therapy (Study NBTXR3-102); an immuno-oncology (I/O) basket trial (Study NBTXR3-1100) which evaluates NBTXR3 in combination with anti-PD-1 in the United States (US); phase I trials evaluating NBTXR3 activated by radiation therapy for the treatment of liver and prostate cancer; a partnership with PharmaEngine in Asia evaluating NBTXR3 in combination with cisplatin; and a clinical collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) including nine (9) trials across several indications.Back To Top
Nanotech company Nanobiotix earns Prix Galien Award for innovation. Appl Rad Oncol.